Design Therapeutics, Inc. (DSGN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Design Therapeutics reported revenue of $0. Net income was -$69.8M, or -$1.22 per diluted share. Operating activities generated -$54.4M of cash, leaving -$54.6M of free cash flow. At fiscal year end, Design Therapeutics held $226.2M in total assets against $13.7M in total liabilities, including $16.9M of cash and equivalents.
Open the full interactive Design Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Design Therapeutics Key Stats
| Share Price | $9.78 |
|---|---|
| Market Cap | $611.3M |
| 52-Week Range | $5.53 – $15.94 |
| Shares Outstanding | 62.5 million (basic, 2026 Q2) |
Design Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M |
| Pre-Tax Income | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Diluted EPS | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 |
Design Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$17.0M | -$16.0M | -$17.6M | -$20.2M |
| Diluted EPS | -$0.30 | -$0.28 | -$0.29 | -$0.32 |
Design Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $298.6M | $26.5M | $21.2M | $22.6M | $16.9M |
| Current Assets | $385.4M | $335.1M | $284.6M | $248.0M | $223.8M |
| Total Assets | $390.6M | $341.1M | $289.6M | $252.1M | $226.2M |
| Current Liabilities | $5.3M | $10.8M | $9.6M | $8.5M | $13.1M |
| Total Liabilities | $8.4M | $13.8M | $12.0M | $10.0M | $13.7M |
| Shareholders' Equity | $382.1M | $327.3M | $277.7M | $242.1M | $212.5M |
Design Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$29.4M | -$51.3M | -$58.6M | -$43.1M | -$54.4M |
| Cash From Investing | -$53.6M | -$221.0M | $52.5M | $44.0M | $22.9M |
| Cash From Financing | $379.2M | $235,000 | $724,000 | $513,000 | $25.7M |
| Free Cash Flow | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M |
Figures from Design Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Design Therapeutics financials page for every line item.
Design Therapeutics Company Profile
| Ticker | DSGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Carlsbad, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001807120 |
Frequently Asked Questions
What was Design Therapeutics' revenue in fiscal 2025?
Design Therapeutics (DSGN) reported revenue of $0 for fiscal 2025.
What is Design Therapeutics' annual revenue history?
Design Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Design Therapeutics' net income in fiscal 2025?
Design Therapeutics reported net income of -$69.8M for fiscal 2025.
What was Design Therapeutics' earnings per share (EPS) in fiscal 2025?
Design Therapeutics' diluted EPS was -$1.22 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Design Therapeutics generate in fiscal 2025?
Design Therapeutics generated -$54.6M of free cash flow in fiscal 2025.
What was Design Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Design Therapeutics reported revenue of $0.
How many shares of Design Therapeutics are outstanding?
Design Therapeutics reported a weighted average of 62.5 million basic shares outstanding in 2026 Q2.
What is Design Therapeutics' market cap?
Based on its latest closing price, Design Therapeutics (DSGN) has a market capitalization of about $611.3M.
When does Design Therapeutics' fiscal year end?
Design Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Design Therapeutics headquartered?
Design Therapeutics lists its business address in Carlsbad, California in its SEC filings.